The only entry here where the consequence is entirely cosmetic and entirely consequential: visible jaundice that harms nobody, and makes people stop taking a drug that was working.
Atazanavir blocks the enzyme that clears bilirubin, and in somebody who already clears it slowly — the UGT1A1 genotype behind Gilbert syndrome — the result is visible jaundice. It is not dangerous. It is, however, the reason people stop taking the drug, and CPIC wrote a guideline about that rather than about toxicity: if a person carries the low-activity genotype, consider a different agent, especially where jaundice would be a reason to discontinue. This is the one note on the site where the pharmacogenomic consequence is entirely cosmetic and entirely consequential.
Whose work this rests on
Every guideline above was written by people. Named here because they are contributors to this page in the same sense anybody else on this site is.
Clinical pharmacology and therapeutics · 2016 · PMID 26417955
Variants MyGeneLog reports for these genes
These are the positions in your own file that carry the genes above. Not every gene in a guideline is one we report — where that is the case the gene appears above without a variant here, and the note says so.
This page is educational and contains no dosing information. Where a clinical guideline covers one of these gene-drug pairs it is written for prescribers and works through validated algorithms alongside clinical monitoring. Nothing here is a reason to start, stop, or change a medication — that conversation belongs with the clinician or pharmacist managing your treatment.